{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T22:39:52Z","timestamp":1790375992712,"version":"4.1.0"},"reference-count":110,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Mycosis fungoides (MF) and Sezary Syndrome (SS) represent the most common subtypes of primary Cutaneous T-cell lymphoma (CTCL). Patients with advanced MF and SS have a poor prognosis leading to an interest in the development of new therapies with targeted mechanisms of action and acceptable safety profiles. In this review we focus on such novel strategies that have changed the treatment paradigm of this rare malignancy.<\/jats:p>","DOI":"10.1186\/1756-8722-5-24","type":"journal-article","created":{"date-parts":[[2012,5,17]],"date-time":"2012-05-17T18:23:31Z","timestamp":1337279011000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Novel therapeutic agents for cutaneous T-Cell lymphoma"],"prefix":"10.1186","volume":"5","author":[{"given":"Salvia","family":"Jain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine","family":"Zain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Owen","family":"O\u2019Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,5,17]]},"reference":[{"key":"226_CR1","doi-asserted-by":"publisher","first-page":"5064","DOI":"10.1182\/blood-2008-10-184168","volume":"113","author":"PT Bradford","year":"2009","unstructured":"Bradford PT, Devesa SS, Anderson WF: Cutaneous lymphoma incidence patters in the United States: a population based study of 3884 cases. Blood. 2009, 113: 5064-5073. 10.1182\/blood-2008-10-184168.","journal-title":"Blood"},{"key":"226_CR2","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","volume":"110","author":"E Olsen","year":"2007","unstructured":"Olsen E, Vonderheid E, Pimpinelli N: Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the international society for cutaneous lymphomas (ISCL) and the cutaneous lymphoma task force of the European organization for research and treatment of cancer (EORTC). Blood. 2007, 110: 1713-1722. 10.1182\/blood-2007-03-055749.","journal-title":"Blood"},{"key":"226_CR3","doi-asserted-by":"publisher","first-page":"4730","DOI":"10.1200\/JCO.2009.27.7665","volume":"28","author":"NS Agar","year":"2010","unstructured":"Agar NS, Wedgeworth E, Crichton S: Survival outcomes and prognostic factors in mycosis fungoides\/Sezary syndrome: validation of the revised international society for cutaneous lymphomas\/European organization for research and treatment of cancer staging proposal. J Clin Oncol. 2010, 28: 4730-4739. 10.1200\/JCO.2009.27.7665.","journal-title":"J Clin Oncol"},{"key":"226_CR4","first-page":"857","volume":"139","author":"YH Kim","year":"1996","unstructured":"Kim YH, Liu HL, Mraz-Gernhard S: Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol. 1996, 139: 857-866.","journal-title":"Arch Dermatol"},{"issue":"4","key":"226_CR5","doi-asserted-by":"crossref","first-page":"436","DOI":"10.6004\/jnccn.2008.0033","volume":"6","author":"SM Horwitz","year":"2008","unstructured":"Horwitz SM, Olsen EA, Duvic M: Review of the treatment of mycosis fungoides and Sezary syndrome: a stage-based approach. J Natl Compr Canc Netw. 2008, 6 (4): 436-442.","journal-title":"J Natl Compr Canc Netw"},{"issue":"8","key":"226_CR6","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.ejca.2006.01.025","volume":"42","author":"F Trautinger","year":"2006","unstructured":"Trautinger F, Knobler R, Willemze R: EORTC consensus recommendations for the treatment of mycosis fungoides\/Sezary syndrome. Eur J Cancer. 2006, 42 (8): 1014-1030. 10.1016\/j.ejca.2006.01.025.","journal-title":"Eur J Cancer"},{"key":"226_CR7","doi-asserted-by":"publisher","first-page":"4337","DOI":"10.1182\/blood-2009-07-202895","volume":"114","author":"HM Prince","year":"2009","unstructured":"Prince HM, Whittaker S, Hoppe RT: How I treat mycosis fungoides and Sezary syndrome. Blood. 2009, 114: 4337-4353. 10.1182\/blood-2009-07-202895.","journal-title":"Blood"},{"key":"226_CR8","doi-asserted-by":"publisher","first-page":"3082","DOI":"10.1182\/blood-2008-05-154609","volume":"112","author":"SO Arulogan","year":"2008","unstructured":"Arulogan SO, Prince HM, Ng J: Long-term outcomes of patients with advanced stage cutaneous T-cell lymphoma and large cell transformation. Blood. 2008, 112: 3082-3087. 10.1182\/blood-2008-05-154609.","journal-title":"Blood"},{"key":"226_CR9","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1200\/JCO.2010.32.0630","volume":"18","author":"EA Olsen","year":"2011","unstructured":"Olsen EA, Whittaker S, Kim YH: Clinical end points and response criteria in mycosis fungoides and sezary syndrome: a consensus statement of the International Society for cutaneous lymphomas, the United States cutaneous lymphoma consortium, and the cutaneous lymphoma task force of the European organization for research and treatment of cancer. J Clin Oncol. 2011, 18: 2598-2607.","journal-title":"J Clin Oncol"},{"key":"226_CR10","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1158\/1078-0432.CCR-08-2788","volume":"15","author":"R Piekarz","year":"2009","unstructured":"Piekarz R, Bates S: Epigenetic modifiers: basic understanding and clinical development. Clin Cancer Res. 2009, 15: 3918-3926. 10.1158\/1078-0432.CCR-08-2788.","journal-title":"Clin Cancer Res"},{"key":"226_CR11","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S1535-6108(03)00165-X","volume":"4","author":"RW Johnstone","year":"2003","unstructured":"Johnstone RW, Licht JD: Histone deacetylase inhibitors in cancer therapy: is transcription the primary target?. Cancer Cell. 2003, 4: 13-18. 10.1016\/S1535-6108(03)00165-X.","journal-title":"Cancer Cell"},{"issue":"6","key":"226_CR12","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1054\/bjoc.2000.1327","volume":"83","author":"V Sandor","year":"2000","unstructured":"Sandor V, Senderowicz A, Mertins S: P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. Br J Cancer. 2000, 83 (6): 817-825. 10.1054\/bjoc.2000.1327.","journal-title":"Br J Cancer"},{"issue":"49","key":"226_CR13","doi-asserted-by":"publisher","first-page":"34940","DOI":"10.1074\/jbc.274.49.34940","volume":"274","author":"LC Sambucetti","year":"1999","unstructured":"Sambucetti LC, Fischer DD, Zabludoff S: Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. J Biol Chem. 1999, 274 (49): 34940-34947. 10.1074\/jbc.274.49.34940.","journal-title":"J Biol Chem"},{"issue":"12","key":"226_CR14","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1038\/nrc950","volume":"2","author":"M Classon","year":"2002","unstructured":"Classon M, Harlow E: The retinoblastoma tumour suppressor in development and cancer. Nat Rev Cancer. 2002, 2 (12): 910-917. 10.1038\/nrc950.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"226_CR15","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1073\/pnas.0307708100","volume":"101","author":"CY Gui","year":"2004","unstructured":"Gui CY, Ngo L, Xu WS: Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci USA. 2004, 101 (5): 1241-1246. 10.1073\/pnas.0307708100.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"18","key":"226_CR16","doi-asserted-by":"publisher","first-page":"10014","DOI":"10.1073\/pnas.180316197","volume":"97","author":"VM Richon","year":"2000","unstructured":"Richon VM, Sandhoff TW, Rifkind RA: Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA. 2000, 97 (18): 10014-10019. 10.1073\/pnas.180316197.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"15","key":"226_CR17","first-page":"4460","volume":"63","author":"MJ Peart","year":"2003","unstructured":"Peart MJ, Tainton KM, Ruefli AA: Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res. 2003, 63 (15): 4460-4471.","journal-title":"Cancer Res"},{"issue":"19","key":"226_CR18","doi-asserted-by":"publisher","first-page":"10833","DOI":"10.1073\/pnas.191208598","volume":"98","author":"AA Ruefli","year":"2001","unstructured":"Ruefli AA, Ausserlechner MJ, Bernhard D: The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci USA. 2001, 98 (19): 10833-10838. 10.1073\/pnas.191208598.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"226_CR19","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1046\/j.1365-2141.2002.03586.x","volume":"118","author":"LK Jones","year":"2002","unstructured":"Jones LK, Saha V: Chromatin modification, leukaemia and implications for therapy. Br J Haematol. 2002, 118 (3): 714-727.","journal-title":"Br J Haematol"},{"issue":"1","key":"226_CR20","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/nm1161","volume":"11","author":"A Nebbioso","year":"2005","unstructured":"Nebbioso A, Clarke N, Voltz E: Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med. 2005, 11 (1): 77-84. 10.1038\/nm1161.","journal-title":"Nat Med"},{"issue":"7","key":"226_CR21","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1158\/0008-5472.CAN-03-2629","volume":"64","author":"F Guo","year":"2004","unstructured":"Guo F, Sigua C, Tao J: Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L\/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells. Cancer Res. 2004, 64 (7): 2580-2589. 10.1158\/0008-5472.CAN-03-2629.","journal-title":"Cancer Res"},{"issue":"18","key":"226_CR22","doi-asserted-by":"publisher","first-page":"11700","DOI":"10.1073\/pnas.182372299","volume":"99","author":"LM Butler","year":"2002","unstructured":"Butler LM, Zhou X, Xu WS: The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc Natl Acad Sci USA. 2002, 99 (18): 11700-11705. 10.1073\/pnas.182372299.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"28","key":"226_CR23","doi-asserted-by":"publisher","first-page":"25562","DOI":"10.1074\/jbc.M201196200","volume":"277","author":"D Wolf","year":"2002","unstructured":"Wolf D, Rodova M, Miska EA: Acetylation of [beta]-catenin by CREB-binding protein (CBP). J Biol Chem. 2002, 277 (28): 25562-25567. 10.1074\/jbc.M201196200.","journal-title":"J Biol Chem"},{"issue":"8","key":"226_CR24","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S0960-9822(00)00445-0","volume":"10","author":"AJ Bannister","year":"2000","unstructured":"Bannister AJ, Miska EA, Gorlich D: Acetylation of importin-a nuclear import factors by CBP\/p300. Curr Biol. 2000, 10 (8): 467-470. 10.1016\/S0960-9822(00)00445-0.","journal-title":"Curr Biol"},{"issue":"5","key":"226_CR25","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/S1097-2765(04)00094-2","volume":"13","author":"HY Cohen","year":"2004","unstructured":"Cohen HY, Lavu S, Bitterman KJ: Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis. Mol Cell. 2004, 13 (5): 627-638. 10.1016\/S1097-2765(04)00094-2.","journal-title":"Mol Cell"},{"issue":"4","key":"226_CR26","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/86507","volume":"7","author":"MS Kim","year":"2001","unstructured":"Kim MS, Kwon HJ, Lee YM: Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med. 2001, 7 (4): 437-443. 10.1038\/86507.","journal-title":"Nat Med"},{"issue":"1","key":"226_CR27","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S0006-291X(02)02787-0","volume":"300","author":"Y Mie Lee","year":"2003","unstructured":"Mie Lee Y, Kim SH, Kim HS: Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1a activity. Biochem Biophys Res Commun. 2003, 300 (1): 241-246. 10.1016\/S0006-291X(02)02787-0.","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"226_CR28","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/j.1365-2559.2008.03109.x","volume":"53","author":"L Marquard","year":"2008","unstructured":"Marquard L, Gjerdrum LM, Christensen IJ: Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma. Histopathology. 2008, 53 (3): 267-277. 10.1111\/j.1365-2559.2008.03109.x.","journal-title":"Histopathology"},{"key":"226_CR29","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1634\/theoncologist.12-10-1247","volume":"12","author":"BS Mann","year":"2007","unstructured":"Mann BS, Johnson JR, Cohen MH: FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist. 2007, 12: 1247-1252. 10.1634\/theoncologist.12-10-1247.","journal-title":"Oncologist"},{"key":"226_CR30","unstructured":"[http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm189629.htm]"},{"key":"226_CR31","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1111\/j.0022-202X.2005.23925.x","volume":"125","author":"C Zhang","year":"2005","unstructured":"Zhang C, Richon V, Ni X: Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells. Relevance to mechanism of therapeutic action. J Invest Dermatol. 2005, 125: 1045-1052. 10.1111\/j.0022-202X.2005.23925.x.","journal-title":"J Invest Dermatol"},{"key":"226_CR32","first-page":"3578","volume":"9","author":"WK Kelly","year":"2003","unstructured":"Kelly WK, Richon VM, O\u2019Connor OA: Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res. 2003, 9: 3578-3588.","journal-title":"Clin Cancer Res"},{"key":"226_CR33","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1200\/JCO.2005.01.9679","volume":"24","author":"OA O\u2019Connor","year":"2006","unstructured":"O\u2019Connor OA, Heaney ML, Schwartz L: Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol. 2006, 24: 166-173. 10.1200\/JCO.2005.01.9679.","journal-title":"J Clin Oncol"},{"key":"226_CR34","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1182\/blood-2006-06-025999","volume":"109","author":"M Duvic","year":"2007","unstructured":"Duvic M, Talpur R, Ni X: Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007, 109: 31-39. 10.1182\/blood-2006-06-025999.","journal-title":"Blood"},{"key":"226_CR35","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","volume":"25","author":"EA Olsen","year":"2007","unstructured":"Olsen EA, Kim YH, Kuzel TM: Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007, 25: 3109-3115. 10.1200\/JCO.2006.10.2434.","journal-title":"J Clin Oncol"},{"key":"226_CR36","volume-title":"Blood","author":"M Duvic","year":"2009","unstructured":"Duvic M, Kim YH, Kuzel TM: The systemic effects of vorinostat in Patients with cutaneous T-cell lymphoma (CTCL): Post-Hoc analysis in patients with high blood tumor burden. Blood. 2009, ASH Annual Meeting Abstracts 114:Abstract 1709"},{"key":"226_CR37","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jaad.2008.11.889","volume":"61","author":"JM Gardner","year":"2009","unstructured":"Gardner JM, Introcaso CE, Nasta SD: A novel regimen of vorinostat with interferon gamma for refractory Sezary syndrome. J Am cad Dermatol. 2009, 61: 112-116. 10.1016\/j.jaad.2008.11.889.","journal-title":"J Am cad Dermatol"},{"key":"226_CR38","doi-asserted-by":"publisher","first-page":"4636","DOI":"10.1182\/blood-2003-09-3068","volume":"103","author":"RL Piekarz","year":"2004","unstructured":"Piekarz RL, Robey RW, Zhan Z: T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood. 2004, 103: 4636-4643. 10.1182\/blood-2003-09-3068.","journal-title":"Blood"},{"key":"226_CR39","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1182\/blood.V98.9.2865","volume":"98","author":"RL Piekarz","year":"2001","unstructured":"Piekarz RL, Robey RW, Sandor V: Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood. 2001, 98: 2865-2868. 10.1182\/blood.V98.9.2865.","journal-title":"Blood"},{"key":"226_CR40","doi-asserted-by":"publisher","first-page":"5410","DOI":"10.1200\/JCO.2008.21.6150","volume":"27","author":"R Piekarz","year":"2009","unstructured":"Piekarz R, Frye R, Turner M: Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2009, 27: 5410-5417. 10.1200\/JCO.2008.21.6150.","journal-title":"J Clin Oncol"},{"issue":"29","key":"226_CR41","doi-asserted-by":"publisher","first-page":"4485","DOI":"10.1200\/JCO.2010.28.9066","volume":"28","author":"S Whittaker","year":"2010","unstructured":"Whittaker S, Demierre MF, Kim EJ: Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol. 2010, 28 (29): 4485-4491. 10.1200\/JCO.2010.28.9066.","journal-title":"J Clin Oncol"},{"key":"226_CR42","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA: New guidelines to evaluate the response to treatment in solid tumors: European organization for research and treatment of cancer, national cancer institute of the United States, national cancer institute of canada. J Natl Cancer Inst. 2000, 92: 205-216. 10.1093\/jnci\/92.3.205.","journal-title":"J Natl Cancer Inst"},{"key":"226_CR43","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME: Revised response criteria for malignant lymphoma. J Clin Oncol. 2007, 25: 579-586. 10.1200\/JCO.2006.09.2403.","journal-title":"J Clin Oncol"},{"key":"226_CR44","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1001\/archderm.138.1.42","volume":"138","author":"SR Stevens","year":"2002","unstructured":"Stevens SR, Ke MS, Parry EJ: Quantifying skin disease burden in mycosis fungoides-type cutaneous T-cell lymphomas: the severity-weighted assessment tool (SWAT). Arch Dermatol. 2002, 138: 42-48. 10.1001\/archderm.138.1.42.","journal-title":"Arch Dermatol"},{"key":"226_CR45","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1749-6632.2001.tb03719.x","volume":"941","author":"P Heald","year":"2001","unstructured":"Heald P: Clinical trials and efficacy assessment in the therapy of cutaneous T-cell lymphoma. Ann NY cad Sci. 2001, 941: 155-165.","journal-title":"Ann NY cad Sci"},{"key":"226_CR46","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1200\/JCO.2001.19.2.376","volume":"19","author":"E Olsen","year":"2001","unstructured":"Olsen E, Duvic M, Frankel A: Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol. 2001, 19: 376-388.","journal-title":"J Clin Oncol"},{"key":"226_CR47","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1056\/NEJM198702053160603","volume":"316","author":"R Edelson","year":"1987","unstructured":"Edelson R, Berger C, Gasparro F: Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherpy: Preliminary result. N Engl J Med. 1987, 316: 297-303. 10.1056\/NEJM198702053160603.","journal-title":"N Engl J Med"},{"key":"226_CR48","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1158\/1078-0432.CCR-07-1786","volume":"14","author":"NL Steele","year":"2008","unstructured":"Steele NL, Plumb JA, Vidal L: A phase I pharmacokinetic and pharmacodynamics study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res. 2008, 14: 804-10.1158\/1078-0432.CCR-07-1786.","journal-title":"Clin Cancer Res"},{"key":"226_CR49","doi-asserted-by":"publisher","first-page":"3762","DOI":"10.1158\/1078-0432.CCR-05-2095","volume":"12","author":"R Piekarz","year":"2006","unstructured":"Piekarz R, Frye R, Wright J: Cardiac studies in patients with depsipeptide, FK28, in a phase II trial for T-cell lymphoma. Clin Cancer Res. 2006, 12: 3762-3773. 10.1158\/1078-0432.CCR-05-2095.","journal-title":"Clin Cancer Res"},{"key":"226_CR50","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/j.1600-0609.2008.01102.x","volume":"81","author":"P Gimsing","year":"2008","unstructured":"Gimsing P, Hansen M, Knudsen LM: A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia. Eur J Haematol. 2008, 81: 170-176. 10.1111\/j.1600-0609.2008.01102.x.","journal-title":"Eur J Haematol"},{"key":"226_CR51","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1007\/s00280-010-1419-5","volume":"67","author":"NL Steele","year":"2011","unstructured":"Steele NL, Plumb JA, Vidal L: Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101). Cancer Chemother Pharmacol. 2011, 67: 1273-1279. 10.1007\/s00280-010-1419-5.","journal-title":"Cancer Chemother Pharmacol"},{"key":"226_CR52","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1200\/jco.2009.27.15_suppl.3531","volume":"27","author":"WK Kelly","year":"2009","unstructured":"Kelly WK, DeBono J, Blumenschein G: Final results of a phase I study of oral belinostat (PXD101) in patients with solid tumors. J Clin Oncol (Meeting Abstracts). 2009, 27: 3531-","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"226_CR53","volume-title":"Blood","author":"B Pohlman","year":"2009","unstructured":"Pohlman B, Advani RH, Duvic M: Final results of a phase II trial of Belinostat (PXD-101) in patients with recurrent ore refractory peripheral or cutaneous T-cell lymphoma. Blood. 2009, ASH Annual Meeting Abstracts 114:Abstract 920"},{"key":"226_CR54","doi-asserted-by":"publisher","first-page":"4500","DOI":"10.1158\/1078-0432.CCR-07-4262","volume":"14","author":"L Ellis","year":"2008","unstructured":"Ellis L, Pan Y, Smyth GK: Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin Cancer Res. 2008, 14: 4500-4510. 10.1158\/1078-0432.CCR-07-4262.","journal-title":"Clin Cancer Res"},{"key":"226_CR55","volume-title":"Blood","author":"M Duvic","year":"2008","unstructured":"Duvic M, Becker JC, Dalle S: Phase II trial of Oral Panobinostat in patients with refractory Cutaneous T-cell Lymphoma. Blood. 2008, ASH Annual Meeting Abstracts 112:Abstract1005"},{"issue":"24","key":"226_CR56","doi-asserted-by":"publisher","first-page":"5306","DOI":"10.1182\/blood-2010-05-284414","volume":"116","author":"A Mandawat","year":"2010","unstructured":"Mandawat A, Fiskus W, Buckley KM: Pan-histone deacetylase (HDAC) inhibitor panobinostat depletes CXCR4 levels and signaling and exerts synergistic anti-myeloid activity in combination with CXCR4 antagonists. Blood. 2010, 116 (24): 5306-5315. 10.1182\/blood-2010-05-284414.","journal-title":"Blood"},{"key":"226_CR57","volume-title":"Blood","author":"C Zhang","year":"2009","unstructured":"Zhang C, Zhang X, Li B: Molecular and biological characteristics of acquired vorinostat-resistant cutaneous T-cell lymphoma cells. Blood. 2009, ASH Annual Meeting Abstracts 114:Abstract 1732"},{"key":"226_CR58","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ccr.2008.12.001","volume":"15","author":"S Fotheringham","year":"2009","unstructured":"Fotheringham S, Epping MT, Stimson L: Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis. Cancer Cell. 2009, 15: 57-66. 10.1016\/j.ccr.2008.12.001.","journal-title":"Cancer Cell"},{"key":"226_CR59","doi-asserted-by":"publisher","first-page":"6532","DOI":"10.1073\/pnas.0913912107","volume":"107","author":"O Khan","year":"2010","unstructured":"Khan O, Fotheringham S, Wood V: HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy. Proc Natl Acad Sci U S A. 2010, 107: 6532-6537. 10.1073\/pnas.0913912107.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"226_CR60","doi-asserted-by":"publisher","first-page":"15s","DOI":"10.1200\/JCO.2008.21.7695","volume":"27","author":"OA O\u2019Connor","year":"2009","unstructured":"O\u2019Connor OA, Pro B, Pinter-Brown LL: Results of the pivotal, multicenter, phase II study of pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). J Clin Oncol. 2009, 27: 15s-10.1200\/JCO.2008.21.7695. suppl; abstr 8561","journal-title":"J Clin Oncol"},{"key":"226_CR61","first-page":"18","volume":"12","author":"FM Sirotnak","year":"1984","unstructured":"Sirotnak FM, DeGraw JI, Moccio DM: New folate analogs of the 10-deaza-aminopterin series: Basis for structural design and biochemical and pharmacologic properties. Cancer Chemother Pharmacol. 1984, 12: 18-25.","journal-title":"Cancer Chemother Pharmacol"},{"key":"226_CR62","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1080\/1042819031000077124","volume":"44","author":"ES Wang","year":"2003","unstructured":"Wang ES, O\u2019Connor OA, She Y: Activity of a novel antifolate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression. Leuk Lymphoma. 2003, 44: 1027-1035. 10.1080\/1042819031000077124.","journal-title":"Leuk Lymphoma"},{"key":"226_CR63","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1007\/s00280-009-0954-4","volume":"64","author":"E Izbicka","year":"2009","unstructured":"Izbicka E, Diaz A, Saunders M: Distince mechansistic activity profile of pralatrexate in comparison to other antifolates in vitro and in vivo molds of human cancers. Cancer Chemother Pharmacol. 2009, 64: 993-999. 10.1007\/s00280-009-0954-4.","journal-title":"Cancer Chemother Pharmacol"},{"key":"226_CR64","volume-title":"Blood","author":"FM Foss","year":"2010","unstructured":"Foss FM, Horwitz SM, Brown LP: Pralatrexate is an effective treatment for heavily pretreated patients with relapsed\/refractory transformed mycosis fungoides (tMF). Blood. 2010, ASH Annual Meeting Abstracts 116:Abstract 1762"},{"key":"226_CR65","volume-title":"Blood","author":"SM Horwitz","year":"2010","unstructured":"Horwitz SM, Kim YH, Foss FM: Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL): Final results of a multicenter dose-finding study. Blood. 2010, ASH Annual Meeting Abstracts 116:Abstract 2800"},{"issue":"14","key":"226_CR66","doi-asserted-by":"publisher","first-page":"3648","DOI":"10.1158\/1078-0432.CCR-10-0671","volume":"16","author":"Marchi Enrica","year":"2010","unstructured":"Enrica Marchi, Luca Paoluzzi, Luigi Scotto: Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies. Clin Cancer Res. 2010, 16 (14): 3648-3658. 10.1158\/1078-0432.CCR-10-0671.","journal-title":"Clin Cancer Res"},{"key":"226_CR67","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1111\/j.1349-7006.2008.01038.x","volume":"100","author":"M Ri","year":"2009","unstructured":"Ri M, Iida S, Ishida T: Bortezomib-induced apoptosis in mature T-cell lymphoma cells partially depends on upregulation of Noxa and functional repression of Mcl-1. Cancer Sci. 2009, 100: 341-348. 10.1111\/j.1349-7006.2008.01038.x.","journal-title":"Cancer Sci"},{"key":"226_CR68","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMoa043445","volume":"352","author":"PG Richardson","year":"2005","unstructured":"Richardson PG, Sonneveld P, Schuster MW: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. New Engl J Med. 2005, 352: 2487-2498. 10.1056\/NEJMoa043445.","journal-title":"New Engl J Med"},{"key":"226_CR69","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1200\/JCO.2005.02.050","volume":"23","author":"OA O\u2019Connor","year":"2005","unstructured":"O\u2019Connor OA, Wright J, Moskowitz C: Phase II clinical experience with the novel proteasome inhibitor bortezomib inpatients with indolent non-Hodgkin\u2019s lymphoma and mantle cell lymphoma. J Clin Oncol. 2005, 23: 676-684. 10.1200\/JCO.2005.02.050.","journal-title":"J Clin Oncol"},{"key":"226_CR70","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/nrc1361","volume":"4","author":"J Adams","year":"2004","unstructured":"Adams J: The proteasome: a suitable antineoplastic target. Nat Rev Cancer. 2004, 4: 349-360. 10.1038\/nrc1361.","journal-title":"Nat Rev Cancer"},{"key":"226_CR71","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1038\/sj.cdd.4400436","volume":"5","author":"B An","year":"1998","unstructured":"An B, Goldfarb RH, Siman R: Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ. 1998, 5: 1062-1075. 10.1038\/sj.cdd.4400436.","journal-title":"Cell Death Differ"},{"key":"226_CR72","first-page":"4342","volume":"58","author":"RZ Orlowski","year":"1998","unstructured":"Orlowski RZ, Eswara JR, Lafond-Walker A: Tumor growth inhibition induced in a murine model of human Burkitt\u2019s lymphoma by a proteasome inhibitor. Cancer Res. 1998, 58: 4342-4348.","journal-title":"Cancer Res"},{"key":"226_CR73","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1182\/blood.V96.1.269","volume":"96","author":"P Masdehors","year":"2000","unstructured":"Masdehors P, Merle-B\u00e9ral H, Maloum K: Deregulation of the ubiquitin system and p53 proteolysis modify the apoptotic response in B-CLL lymphocytes. Blood. 2000, 96: 269-274.","journal-title":"Blood"},{"key":"226_CR74","first-page":"4996","volume":"62","author":"R LeBlanc","year":"2002","unstructured":"LeBlanc R, Catley LP, Hideshima T: Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res. 2002, 62: 4996-5000.","journal-title":"Cancer Res"},{"key":"226_CR75","first-page":"3071","volume":"61","author":"T Hideshima","year":"2001","unstructured":"Hideshima T, Richardson P, Chauhan D: The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001, 61: 3071-3076.","journal-title":"Cancer Res"},{"issue":"27","key":"226_CR76","doi-asserted-by":"publisher","first-page":"4293","DOI":"10.1200\/JCO.2007.11.4207","volume":"25","author":"PL Zinzani","year":"2007","unstructured":"Zinzani PL, Musuraca G, Tani M: Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007, 25 (27): 4293-4297. 10.1200\/JCO.2007.11.4207.","journal-title":"J Clin Oncol"},{"issue":"12","key":"226_CR77","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1093\/annonc\/mdn431","volume":"19","author":"J Lee","year":"2008","unstructured":"Lee J, Suh C, Kang HJ: Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK\/T-cell lymphoma. Ann Oncol. 2008, 19 (12): 2079-2083. 10.1093\/annonc\/mdn431.","journal-title":"Ann Oncol"},{"key":"226_CR78","doi-asserted-by":"publisher","first-page":"6383","DOI":"10.1158\/0008-5472.CAN-06-4086","volume":"67","author":"DD Susan","year":"2007","unstructured":"Susan DD, Christopher JK, Monette A: Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res. 2007, 67: 6383-6391. 10.1158\/0008-5472.CAN-06-4086.","journal-title":"Cancer Res"},{"issue":"15s","key":"226_CR79","doi-asserted-by":"crossref","first-page":"Abstract8537","DOI":"10.1200\/jco.2009.27.15_suppl.8537","volume":"27","author":"R Vij","year":"2009","unstructured":"Vij R, Wang M, Orlowski R: PX-171-004, a multicenter phase II study of carfilzomib in patients with relapsed myeloma: An efficacy update. J Clin Oncol. 2009, 27 (15s): Abstract8537-","journal-title":"J Clin Oncol"},{"key":"226_CR80","volume-title":"Blood","author":"L Wang","year":"2009","unstructured":"Wang L, Siegel D, Kaufman JL: Updated results of bortezomib-na\u00efve patients in PX-171-004, an ongoing open label, phase II study of single agent carfilzomib in patients with relapsed or refractory MM. Blood. 2009, ASH Annual meeting Abstracts 114:Abstract 302"},{"issue":"15s","key":"226_CR81","doi-asserted-by":"crossref","first-page":"Abstract8552","DOI":"10.1200\/jco.2009.27.15_suppl.8552","volume":"27","author":"M Duvic","year":"2009","unstructured":"Duvic M, Forero-Torres A, Foss F: Long-term treatment of CTCL with oral PNP inhibitor, forodesine. J Clin Oncol. 2009, 27 (15s): Abstract8552-","journal-title":"J Clin Oncol"},{"issue":"2","key":"226_CR82","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S0145-2126(97)00158-6","volume":"22","author":"L Ginaldi","year":"1998","unstructured":"Ginaldi L, Martinis M, Matutes E: Levels of expression of CD52 in normal and leukemic B and T cells: Correlation with in vivo therapeutic responses to Campath-1H. Leuk Res. 1998, 22 (2): 185-191. 10.1016\/S0145-2126(97)00158-6.","journal-title":"Leuk Res"},{"key":"226_CR83","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1385\/MO:20:4:389","volume":"20","author":"S Capalbo","year":"2003","unstructured":"Capalbo S, Delia M, Dargenio M: Mycosis fungoides\/Sezary syndrome: a report of three cases treated with Campath-IH as salvage treatment. Medical Oncology. 2003, 20: 389-396. 10.1385\/MO:20:4:389.","journal-title":"Medical Oncology"},{"key":"226_CR84","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1034\/j.1600-0609.2003.00143.x","volume":"71","author":"GA Kennedy","year":"2003","unstructured":"Kennedy GA, Seymour JF, Wolf M: Treatment of patients with advanced mycosis fungoides and Sezary syndrome with alemtuzumab. Eur J Haematol. 2003, 71: 250-256. 10.1034\/j.1600-0609.2003.00143.x.","journal-title":"Eur J Haematol"},{"key":"226_CR85","doi-asserted-by":"publisher","first-page":"4267","DOI":"10.1182\/blood-2002-09-2802","volume":"101","author":"J Lundin","year":"2003","unstructured":"Lundin J, Hagberg H, Repp R: Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides\/Sezary syndrome. Blood. 2003, 101: 4267-4272. 10.1182\/blood-2002-09-2802.","journal-title":"Blood"},{"key":"226_CR86","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1046\/j.0902-4441.2004.00169.x","volume":"72","author":"O Gautschi","year":"2004","unstructured":"Gautschi O, Blumenthal N, Streit M: Successful treatment of chemotherapy refractory Sezary syndrome with alemtuzumab (Campath-1H). Eur J Haematol. 2004, 72: 61-63. 10.1046\/j.0902-4441.2004.00169.x.","journal-title":"Eur J Haematol"},{"key":"226_CR87","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.3109\/10428190903216770","volume":"50","author":"C Querfeld","year":"2009","unstructured":"Querfeld C, Mehta N, Rosen T: Alemtuzumb for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center. Leuk Lymphoma. 2009, 50: 1969-1976. 10.3109\/10428190903216770.","journal-title":"Leuk Lymphoma"},{"key":"226_CR88","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1182\/blood-2004-02-0593","volume":"104","author":"G Hale","year":"2004","unstructured":"Hale G, Rebello P, Brettman LR: Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. Blood. 2004, 104: 948-955. 10.1182\/blood-2004-02-0593.","journal-title":"Blood"},{"key":"226_CR89","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/j.leukres.2007.11.009","volume":"32","author":"L Alinari","year":"2008","unstructured":"Alinari L, Geskin L, Grady T: Subcutaneous alemtuzumab for Sezary syndrome in the very elderly. Leuk Res. 2008, 32: 1299-1303. 10.1016\/j.leukres.2007.11.009.","journal-title":"Leuk Res"},{"issue":"5","key":"226_CR90","first-page":"702","volume":"90","author":"PL Zinzani","year":"2005","unstructured":"Zinzani PL, Alinari L, Tani M: Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma. Haematologica. 2005, 90 (5): 702-703.","journal-title":"Haematologica"},{"key":"226_CR91","doi-asserted-by":"publisher","first-page":"784","DOI":"10.3324\/haematol.11127","volume":"92","author":"MG Bernengo","year":"2007","unstructured":"Bernengo MG, Quaglino P, Comessatti A: Low-dose of intermittent alemtuzumab in the treatment of Sezary syndrome: clinical and immunologic findings in 14 patients. Haematologica. 2007, 92: 784-794. 10.3324\/haematol.11127.","journal-title":"Haematologica"},{"key":"226_CR92","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/blood.V77.1.20.20","volume":"77","author":"SJ Knox","year":"1991","unstructured":"Knox SJ, Levy R, Hodgkinson S: Observations on the effect of chimeric anti-CD4 monoclonal antibody in patients with mycosis fungoides. Blood. 1991, 77: 20-30.","journal-title":"Blood"},{"key":"226_CR93","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood.V87.3.893.bloodjournal873893","volume":"87","author":"S Knox","year":"1996","unstructured":"Knox S, Hoppe RT, Maloney D: Treatment of cutaneous T-cell lymphoma with chimeric anti-CD4 monoclonal antibody. Blood. 1996, 87: 893-899.","journal-title":"Blood"},{"key":"226_CR94","doi-asserted-by":"publisher","first-page":"4655","DOI":"10.1182\/blood-2006-12-062877","volume":"109","author":"Y Kim","year":"2007","unstructured":"Kim Y, Duvic M, Obitz E: Clinical efficacy of zanolimumab (HuMax-CD4): two phase II studies in refractory cutaneous T-cell lymphoma. Blood. 2007, 109: 4655-4662. 10.1182\/blood-2006-12-062877.","journal-title":"Blood"},{"key":"226_CR95","first-page":"3736","volume":"62","author":"AF Wahl","year":"2002","unstructured":"Wahl AF, Klussman K, Thompson JD: The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin\u2019s disease. Cancer Res. 2002, 62: 3736-3742.","journal-title":"Cancer Res"},{"key":"226_CR96","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1182\/blood-2007-07-099317","volume":"111","author":"NL Bartlett","year":"2008","unstructured":"Bartlett NL, Younes A, Carabasi MH: A phase I multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. Blood. 2008, 111: 1848-1854. 10.1182\/blood-2007-07-099317.","journal-title":"Blood"},{"key":"226_CR97","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.1200\/JCO.2006.07.8972","volume":"25","author":"SM Ansell","year":"2007","unstructured":"Ansell SM, Horwitz SM, Engert A: Phase I\/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin\u2019s lymphoma and anaplastic large-cell lymphoma. J Clin Oncol. 2007, 25: 2764-2769. 10.1200\/JCO.2006.07.8972.","journal-title":"J Clin Oncol"},{"key":"226_CR98","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/nrclinonc.2010.189","volume":"8","author":"A Younes","year":"2011","unstructured":"Younes A: Beyond chemotherapy: new agents for targeted treatment of lymphoma. Nat Rev Clin Oncol. 2011, 8: 85-96. 10.1038\/nrclinonc.2010.189.","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"226_CR99","doi-asserted-by":"publisher","first-page":"6217","DOI":"10.1158\/1078-0432.CCR-09-0162","volume":"15","author":"M Duvic","year":"2009","unstructured":"Duvic M, Reddy S, Pinter Brown L: A phase II study of SGN- 30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders. Clin Cancer Res. 2009, 15 (9): 6217-6224. 10.1158\/1078-0432.CCR-09-0162.","journal-title":"Clin Cancer Res"},{"key":"226_CR100","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","volume":"363","author":"A Younes","year":"2010","unstructured":"Younes A, Bartlett NL, Leonard JP: Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010, 363: 1812-1821. 10.1056\/NEJMoa1002965.","journal-title":"N Engl J Med"},{"key":"226_CR101","first-page":"8500","volume":"27","author":"NL Bartlett","year":"2009","unstructured":"Bartlett NL, Forero-Torres A, Rosenblatt J: Complete remissions with weekly dosing of SGN-35, a novel antibody-drug conjugate (ADC) targeting CD30, in a phase I dose-escalation study in patients with relapsed or refractory Hodgkin lymphoma (HL) or systemic anaplastic large cell lymphoma (sALCL). ASCO Meeting Abstracts. 2009, 27: 8500-","journal-title":"ASCO Meeting Abstracts"},{"key":"226_CR102","first-page":"8031","volume":"29","author":"RW Chen","year":"2011","unstructured":"Chen RW, Gopal AK, Smith SE: Results from a pivotal phase II study of brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma (HL). ASCO Meeting Abstracts. 2011, 29: 8031-","journal-title":"ASCO Meeting Abstracts"},{"key":"226_CR103","first-page":"8032","volume":"29","author":"B Pro","year":"2011","unstructured":"Pro B, Advani R, Brice P: Durable remissions with brentuximab vedotin (SGN-35): Updated results of a phase II study in patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL). ASCO Meeting Abstracts. 2011, 29: 8032-","journal-title":"ASCO Meeting Abstracts"},{"key":"226_CR104","volume-title":"Blood","author":"R Dummer","year":"2010","unstructured":"Dummer R, Whittaker S, Hasan B: EORTC 21012: Phase II multicenter study of CaelyxTM monotherapy in patients with advanced mycosis fungoides stage IIb, IVa and IVb with or without previous chemotherapy. Blood. 2010, ASH Annual Meeting Abstracts 116:Abstract 2823"},{"key":"226_CR105","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1038\/sj.jid.5700322","volume":"126","author":"C Querfeld","year":"2006","unstructured":"Querfeld C, Rizvi MA, Kuzel TM: The selective protein kinase C beta inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway. J Invest Dermatol. 2006, 126: 1641-1647. 10.1038\/sj.jid.5700322.","journal-title":"J Invest Dermatol"},{"key":"226_CR106","doi-asserted-by":"publisher","first-page":"4092","DOI":"10.1200\/JCO.2005.05.3447","volume":"24","author":"MA Carducci","year":"2006","unstructured":"Carducci MA, Musib L, Kies MS: Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinse C beta inhibitor, in patients with advanced cancer. J Clin Oncol. 2006, 24: 4092-4099. 10.1200\/JCO.2005.05.3447.","journal-title":"J Clin Oncol"},{"issue":"8","key":"226_CR107","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.3109\/10428194.2011.572265","volume":"52","author":"C Querfeld","year":"2011","unstructured":"Querfeld C, Kuzel TM, Kim YH: Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma. Leuk Lymphoma. 2011, 52 (8): 1474-1480. 10.3109\/10428194.2011.572265.","journal-title":"Leuk Lymphoma"},{"issue":"28","key":"226_CR108","doi-asserted-by":"publisher","first-page":"4324","DOI":"10.1200\/JCO.2010.28.9793","volume":"28","author":"J Brody","year":"2010","unstructured":"Brody J, Ai W, Czerwinski D: In situ vaccination of a TLR9 agonist induces systemic lymphoma regression. J Clin Oncol. 2010, 28 (28): 4324-4332. 10.1200\/JCO.2010.28.9793.","journal-title":"J Clin Oncol"},{"key":"226_CR109","volume-title":"Blood","author":"YH Kim","year":"2011","unstructured":"Kim YH, Gratzinger D, Harrison C: In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase I\/II study. Blood. 2011, published ahead of print November 1"},{"issue":"13","key":"226_CR110","first-page":"38","volume":"2","author":"C Querfeld","year":"2006","unstructured":"Querfeld C, Kuzel TM, Guitart J: Lenalidomide (Revlimid\u00ae) in patients with cutaneous T-cell lymphoma. Haematol Rep. 2006, 2 (13): 38-39.","journal-title":"Haematol Rep"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1756-8722-5-24.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T19:23:41Z","timestamp":1630524221000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/1756-8722-5-24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,17]]},"references-count":110,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["226"],"URL":"https:\/\/doi.org\/10.1186\/1756-8722-5-24","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,17]]},"assertion":[{"value":"15 February 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2012","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2012","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"24"}}